Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently

Latest news

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    At the moment no PI3K inhibitor has been approved for use in breast cancer, although Gilead Sciences’ Zydelig (idelalisib) has been used for certain types of leukaemia and lymphoma for several

  • Bayer bags speedy US approval for lymphoma drug Aliqopa Bayer bags speedy US approval for lymphoma drug Aliqopa

    Zydelig (idelalisib) – the first-in-class PI3k inhibitor – is approved for relapsed follicular lymphoma and also chronic lymphocytic leukaemia, but saw its commercial prospects scuppered last year after reports of serious

  • Bayer's lymphoma drug copanlisib gets speedy FDA review Bayer's lymphoma drug copanlisib gets speedy FDA review

    Bayer is in pursuit of Gilead Sciences' P13K inhibitor Zydelig (idelalisib), which is already approved for FL and chronic lymphocytic leukaemia (CLL) in the US but hasn't lived up to ... It's worth noting that idelalisib targets a single P13K isoform

  • EU clears AbbVie's leukaemia drug venetoclax EU clears AbbVie's leukaemia drug venetoclax

    have either failed chemoimmunotherapy or are unsuitable for treatment with a B-cell receptor pathway inhibitor such as AbbVie and Johnson &Johnson's Imbruvica (ibrutinib) or Gilead Science's Zydelig (idelalisib). ... had been previously treated with and

  • Roche in Roche in "unprecedented" launch period for new medicines

    Gazyva's gains came despite increased competition in the CLL market from drugs such as AbbVie/Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Science's Zydelig (idelalisib) and a failed trial

More from news
Approximately 4 fully matching, plus 30 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics